Feb 23, 2018 - Dynavax’s commercialization efforts with HEPLISAV-B get a boost.GW Pharmaceuticals’ GWP42006 fails in proof-of-concept study.Sangamo inks a deal with Gilead’s Kite Pharma unit.
Feb 22, 2018 - Halvorsen's 13F portfolio value increased from $15.44B to $16.26B. The number of positions remained steady at 59.Viking Global increased Anthem, Parsley Energy, and Domino’s Pizza while reducing Alpha
Feb 22, 2018 - Whipsaw day with the sharp move down at the close making market direction unclear. GW Pharma’s (GWPH) cannabinoid drug GWP42006 (cannabidivarin, CBDV) failed to meet the endpoints in a phase 2a study
Feb 21, 2018 - I have been on the planet for 60+ years, and this is starting to look more like a general market “crash” than a “correction”.The first rule I was taught pre-1980 as an undergraduate student was “don’t
Feb 20, 2018 - Private and public funds are throwing tens of million of dollars in anticipation of several industry catalysts that will be seen in 2018.New ETFs are coming online that are heavily investing in top co
Feb 10, 2018 - GW Pharmaceuticals looks attractive following recent pullback.Seattle Genetics has entered into a collaboration and license agreement with Pieris Pharmaceuticals.Catalyst Bioscience announced topline
Feb 08, 2018 - Granite Point Capital Management, L.p. Buys GW Pharmaceuticals PLC, Zogenix Inc, Sage Therapeutics Inc, Sells Himax Technologies Inc, MINDBODY Inc, Advanced Micro Devices Inc, Stocks: ZGNX,NTES,GOOGL,CEVA,GOOS,AXTI,GWPH,SAGE,WNC,CDNA,, release date:Feb 08, 2018
Feb 08, 2018 - ETFMG Alternative Harvest ETF is the only U.S. marijuana fund.Recent report indicates the ETF's custodian, Bancorp, is considering dropping the fund due to legal concerns.We think the risk is remote a
Feb 07, 2018 - The DOW was down 8.5% from record highs at the close on Monday, February 5, 2018; the public watches and reacts to the DOW.A partial recovery occurred on Tuesday, February 6, 2018; I started capturing
Feb 07, 2018 - Nabriva has a major catalyst coming up. GW Pharmaceuticals’ marketing application for Epidiolex accepted by EMA. ContraVir announces results from early stage study of Hep B candidate TXL.